Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseases

Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseases
Artiva unveils AlloNK data at EULAR

Artiva Biotherapeutics, Inc. will unveil five accepted abstracts featuring its AlloNK therapeutic at EULAR 2026. These presentations will cover clinical and translational findings across rheumatologic diseases, specifically focusing on refractory rheumatoid arthritis, Sjögren disease, and systemic sclerosis.

Among the highlights is a late-breaking oral presentation, underscoring the company’s ongoing research efforts in advancing next-generation immunotherapies for challenging autoimmune conditions.

Artiva recently reported initial positive results for its AlloNK therapy and announced plans to advance to a Phase 3 rheumatoid arthritis trial in 2026. The company continues to expand its clinical pipeline in rheumatologic diseases. AlloNK remains a central focus of its immunotherapy development program.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.